TB-500 (5MG)

TB-500 — Thymosin Beta-4 active fragment 17-23 — is a 7-residue research-reference peptide derived from the cytoplasmic actin-sequestering protein thymosin-β-4. BioFusion supplies a 5mg vacuum-sealed lyophilized vial.

Research context

TB-500 is the standard reference peptide for thymosin-β-4-actin-binding research panels. The full thymosin-β-4 protein is a 43-residue molecule whose actin-binding activity centers on the central acetylated motif Ac-LKKTETQ — the TB-500 reference peptide. Frequently studied alongside BPC-157 in comparative tissue-repair-chemistry literature. The reference library hosts a series of chemistry-first walkthroughs.

Synthesis & documentation

Produced by solid-phase peptide synthesis using Fmoc protecting-group strategy in a U.S.-based ISO 9001:2008 facility. Each lot is verified for identity (LC-MS), purity (reverse-phase HPLC-UV ≥99.0%), moisture (Karl Fischer), and counter-ion (ion chromatography). The signed Certificate of Analysis ships with every order; lot history available on the COA library.

Storage & handling

Lyophilized TB-500 is stable at −20 °C for the printed shelf life. After reconstitution, the standard 14-day-at-2-8 °C reference window applies; avoid freeze-thaw cycling. The BioFusion reconstitution calculator simplifies any working-concentration math.

Why BioFusion

The TB-500 vs full-length thymosin-β-4 distinction matters — many third-party suppliers sell the full-length protein under the TB-500 SKU at a higher price point. BioFusion’s TB-500 is the canonical 17-23 fragment, verified by LC-MS at every release. Batch transparency ledger shows synthesis-date and HPLC-purity for every lot. Bulk discounts trigger at three+ vials; members save 25% plus free U.S. shipping for 365 days.

For research and laboratory use only. This product is not a drug, food, or cosmetic, and is not intended for diagnostic, therapeutic, or in vivo human use.